MedTrace Logo

Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

NCT01826370 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 678

Last updated 2014-09-18

Study results available
· View outcomes & findings →

Summary

This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Linagliptin

tablet

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01826370 on ClinicalTrials.gov